Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (EVOKE-01)
Marzowiecki Szpital Wojewodzki sw Jana Pawla II Wsiedicach sp. z.o.o Siedickie centrum onkoiogii(0.0 mi away)Contact
+140 other location
epidermal growth factor receptor
epidermal growth factor
The primary objective of this study is to compare overall survival (OS) of sacituzumab
govitecan-hziy (SG) versus docetaxel in participants with advanced or metastatic non-small
cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy and
anti-programmed death protein 1 (PD-1)/ programmed death ligand 1 (PD-L1) immunotherapy
received either in combination or sequentially.
Participants will be randomly assigned in a 1:1 ratio to receive either SG or docetaxel.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.